Leerink Partners Cuts AnaptysBio (NASDAQ:ANAB) Price Target to $81.00

AnaptysBio (NASDAQ:ANAB) had its price objective cut by Leerink Partners from $90.00 to $81.00 in a research report sent to investors on Wednesday morning, MarketBeat.com reports. They currently have an outperform rating on the biotechnology company’s stock.

Other equities analysts have also recently issued reports about the stock. HC Wainwright reiterated a “buy” rating and issued a $95.00 price target on shares of AnaptysBio in a research report on Tuesday. Scotiabank downgraded shares of AnaptysBio to a “hold” rating and set a $70.00 price objective on the stock. in a research report on Tuesday, August 25th. Cantor Fitzgerald restated an “overweight” rating on shares of AnaptysBio in a research note on Tuesday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of AnaptysBio in a report on Friday, August 7th. Finally, Zacks Research downgraded shares of AnaptysBio from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, June 2nd. Twelve equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $79.15.

AnaptysBio Stock Down 1.4%

ANAB opened at $51.00 on Wednesday. The firm has a market cap of $1.52 billion, a price-to-earnings ratio of 9.50 and a beta of 0.71. AnaptysBio has a 52 week low of $13.86 and a 52 week high of $72.36. The business’s 50 day moving average is $55.38 and its two-hundred day moving average is $59.09.

AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings data on Monday, September 21st. The biotechnology company reported $5.11 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.46) by $5.57. The company had revenue of $27.49 million during the quarter, compared to analysts’ expectations of $14.06 million. AnaptysBio had a return on equity of 112.00% and a net margin of 82.37%.During the same quarter in the previous year, the business earned ($1.30) earnings per share. Equities analysts expect that AnaptysBio will post -1.48 EPS for the current fiscal year.

Hedge Funds Weigh In On AnaptysBio

Hedge funds and other institutional investors have recently bought and sold shares of the company. Tema ETFs LLC increased its stake in shares of AnaptysBio by 0.6% during the second quarter. Tema ETFs LLC now owns 31,270 shares of the biotechnology company’s stock worth $2,111,000 after acquiring an additional 201 shares during the period. Arizona State Retirement System lifted its position in AnaptysBio by 13.5% in the second quarter. Arizona State Retirement System now owns 4,363 shares of the biotechnology company’s stock valued at $295,000 after purchasing an additional 518 shares during the period. Persistent Asset Partners Ltd purchased a new stake in AnaptysBio in the 2nd quarter valued at approximately $39,000. Caitong International Asset Management Co. Ltd boosted its holdings in AnaptysBio by 940.8% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,530 shares of the biotechnology company’s stock valued at $74,000 after purchasing an additional 1,383 shares in the last quarter. Finally, Group One Trading LLC acquired a new position in AnaptysBio during the 2nd quarter worth approximately $140,000.

AnaptysBio Company Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines for cancer and immune-mediated diseases. The company’s programs are designed to modulate immune-cell signaling and address conditions in which the immune system is either insufficiently active, as in cancer, or overly active, as in autoimmune and inflammatory disorders.

AnaptysBio’s pipeline has included rosnilimab, an investigational antibody targeting CD200R1, and other immune-cell modulators aimed at autoimmune and inflammatory diseases.